EUCTR2010-021361-69-HU进行中（未招募）不适用
A multicenter, open-label study to assess pharmacokinetics, efficacy, tolerability and safety of Rupatadine in paediatrics patients (2-5 years old) with allergic rhinitis.
J. Uriach y Compañía, S.A.0 个研究点目标入组 40 人开始时间: 2010年7月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •(1)Boys and girls between 2 and 5 years old, inclusive, at screening.
- •(2)Weight 10 Kg.
- •(3)Documented history of mild-moderate allergic rhinitis, susceptible to oral antihistamine treatment in the opinion of the investigator.
- •(4)5TSS 6 during at least the last 2 days before inclusion.
- •(5)Skin Prick test positive of 3 mm greater than the diluent control or a positive ImmunoCAP / RAST test.
- •(6)Results of standard laboratory tests within acceptable limits as assessed by investigator.
- •(7)A 12 lead ECG obtained at screening within acceptable limits, moreover in absence of any drug effect or disease, QTc interval values (msec) after Fridericia’s correction must be normal (not prolonged). The values considered to be normal are 450 msec.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •(1)Clinically relevant abnormal physical findings which could interfere with the objectives of the study, or children with disabilities, developmental delay, psychological problems, or behavioural problems.
- •(2)Clinically relevant abnormal laboratory values indicative of physical illness.
- •(3)Ascertained of presumptive hypersensitivity to the active principle and/or formulation ingredients of the tested compounds such as children with lactose intolerance.
- •(4)Children under any systemic or topical medication for AR and/or an inferior wash-out period as stated as follows: corticosteroids (oral and nasal 28 days, topical dermatological 14 days), cromones (14 days), 1st generation antihistamines, like chlorpheniramine, diphenhydramine, mequitazine or ocular, 7 days; 2nd generation, like loratadine, desloratadine, cetirizine, levocetirizine, 7 days, nasal decongestants (1-3 days), leukotriene inhibitors (3 days), herbal remedies (3 days), systemic antibiotics (14 days), anticholinergic (7 days), any potential inhibitor of CYP3A4 such as ketoconazole, erythromycin and/or tricyclic antidepressants, e.g. imipramin, amitriptilin, (28 days), ophthalmic non-steroidal anti-inflammatory drugs (3 days), nasal-ophthalmic wash solutions (12 h) and immunotherapy.
- •Regular schedule immunotherapy can be maintained throughout the study but will be disallowed from 24h prior to first study dosing.
- •Inhaled ?2 bronchodilators (salbutamol) or long acting (formoterol, salmeterol) are permitted. Children with mild asthma treated with inhaled corticosteroids of = 250 mcg/day for fluticasone ? 400 mcg/day for budesonide or ? 160 mcg/day for ciclesonide will be allowed in the study.
- •(5)Children taking medication that is known to interact significantly with CYP3A4 isozyme of cytochrome P450 such as amiodarone, carbamazapine, cyclosporin, terfenadine, glucocorticoids, phenytoin, rifampicin, antivirals, erythromycin, ketoconazole as well as grapefruit juice.
- •(6)Children that after review of their medical history, are considered by the investigator as unresponsive to antihistaminic treatment.
- •(7)Children whose health could be harmed by their participation in the study at investigator criteria.
- •(8)History of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers may impact on the outcome of the study.
- •(9)Relevant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, haematological, endocrine or neurological diseases that may interfere with the aim of the study.
- •(10)History of chronic nasal or upper respiratory symptoms/disorders, nasal polyps and significant deviation of nasal septum.
- •(11)History of non-allergic rhinitis (vasomotor, infectious, obstructive nasal polyposis, drug-induced, etc).
- •(12)Chronic sinusitis or severe bronchial asthma.
- •(13)Any ear, nose, or throat (ENT) infection in the last 15 days before the baseline visit or any associated ENT disease or temperature ? 38.5ºC at the baseline visit.
- •(14)Children unable to comply with the study requirements (attendance to visits), unable (and their parents) to complete the patient diary and take the study treatment, or children who have to travel to another geographic area during the course of the study.
- •(15)Children taking drugs strongly associated with torsade de pointes such as disopyramide, procainamide, quinidine, amiodarone, sotalol, thioridazine, beperidil or prenylamine.
研究者
相似试验
已完成
不适用
A multi-center, open-label study to assess pharmacokinetics of TKI258 in adult cancer patients with normal and impaired hepatic functiohepatic impairment1001965410027656NL-OMON39786ovartis7
进行中（未招募）
1 期
Study to find the most promising therapeutic dosage of zamicastat for the treatment of PAH disease.Pulmonary arterial hypertensionEUCTR2018-002448-10-ATBial - Portela & Ca, S.A.40
进行中（未招募）
1 期
Multi centre study to assess the safety, effective and movement of Zamicastat within the body when given to a patient with pulmonary arterial hypertension as an additional medication.Pulmonary arterial hypertensionMedDRA version: 21.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2018-002448-10-GBBial - Portela & Ca, S.A32
进行中（未招募）
1 期
Study to find the most promising therapeutic dosage of zamicastat for the treatment of PAH disease.Pulmonary arterial hypertensionEUCTR2018-002448-10-ESBial - Portela & Ca, S.A.40
进行中（未招募）
1 期
Study to find the most promising therapeutic dosage of zamicastat for the treatment of PAH disease.Pulmonary arterial hypertensionEUCTR2018-002448-10-ITBIAL-Portela & Ca, S.A.40